Maija Itälä-Remes profile picture
Maija
Itälä-Remes
Professor, Internal Medicine
MD, PhD, Adjunct professor

Contact

Links

Curriculum.pdf
Publications Full.pdf

Areas of expertise

Haematology
Acute Leukemia
Haematopoietic Stem Cell Transplantation

Biography

Academic degrees:

Medical doctor 26.5.1986, University of Turku, Finland
Doctoral thesis (”B-cell Chronic Lymphocytic Leukemia and Increased Susceptibility to Infections”) and 13.9.1996, University of Turku
Doctorate, PhD 4.12.1997, University of Turku
Adjunct professor Internal Medicine/Clinical Haematology 18.4.2005, University of Turku

Professional appointments:

Resident/specialist in Internal Medicine and in Anaesthesia 1986-1997 Turku University Central Hospital.
Clinical haematologist, Turku University Central Hospital 1997-2007.
Medical Adviser, Janssen-Cilag, Nordic Section 2007-2008.  
Head of Department of Haematology, Tampere University Central Hospital 2008-2010.
Head of Stem Cell Transplant Unit, Turku University Hospital 2010-2017.
Head of Stem Cell Transplant Unit, Helsinki University Hospital 2017-2018.
Head of Division of Clinical Haematology and Stem Cell Transplant Unit, Programme Director of Stem Cell Transplant Unit, Turku University Central Hospital 2018-

Dissertations:

Supervisor 3, Opponent 2, Reviewer 4

Other academic appontments:

Review of the scientific work for docent application

Appointments in Scientific Societies:

Chair of the Finnish Society of Haematology 2012-2014, member 2014-.
Chair of the Finnish Acute Leukemia Working Group 2015-2018, member 2018-
The Nordic-Dutch Working Group for CLL (Chronic Lymphocytic Leukemia) Group, member 2000-2014.
The Finnish Haematology Registry and Biobank, member of the Steering group 2012-2014.
The European Group for Blood and Marrow Transplantation, member 1997-

Duties with National Authorities:

Consultant of the Parliament (Implementation of EU directives into National legislation) 2006-2007
Consultant of the Ministry of Social Affairs and Health (STM) 2016
Consultant of the Finnish Medicine Agency (Fimea) 2016-2018
EU consultation Brussels 2017

Activities in Quality Management:

Inspector exam of FACT/JACIE Quality Management System 31.5.2011, Rotterdam.
Establishment of the Quality Management System of the Stem Cell Unit of Turku University Hospital 2006; Moderation of initial JACIE accreditation and two re-accreditations 2006-2017 Turku University Central Hospital, Turku.


Teaching

Lectures at Finnish University Hospitals and Central Hospitals

Public lectures

Lectures at International meetings

Education of residents and junior colleagues (Clinical haematology and Stem Cell Transplantations)

Member of Faculty of the International Congress on Stem Cell Transplantation and Cellular Therapies, Berlin 2017

Research

Scientific publications and text book articles in field of stem cell transplantions and haematological malignancies

Principal Investigator and Sub-investigator of International Multicentre Clinical Trials

GCP training, latest update 22.2.2018

Publications

Sort by:

B-cell receptor stereotyped subsets and outcome for patients with chronic lymphocytic leukemia in the HOVON 68 trial (2021)

Journal of Translational Genetics and Genomics
Vojdeman F.J., Pedersen L.B., Te Raa D., Juvonen V., van Norden Y., Tjønnfjord G.E., Kimby E., Itälä-Remes M., Rosenquist R., Langerak A.W., Evers L.M., Zenz T., Walewski J., van Oers M.H.J., Geisler C.H., Kater A.P., Niemann C.U.
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021)

Clinical Cancer Research
Mäkelä Eleonora, Pavic Karolina, Varila Taru, Salmenniemi Urpu, Löyttyniemi Eliisa, Nagelli Srikar G., Ammunét Tea, Kähäri Veli-Matti, Clark Richard E., Elo Laura L., Bachanaboyina Venkata Kumari, Lucas Claire M., Itälä-Remes Maija, Westermarck Jukka
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Cytogenetic risk score maintains its prognostic significance inAMLpatients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation (2020)

American Journal of Hematology
Arnon Nagler, Myriam Labopin, Jonathan Canaani, Riitta Niittyvuopio, Gerard Socié, Nicolaus Kröger, Maija Itälä‐Remes, Ibrahim Yakoub‐Agha, Hélène Labussière‐Wallet, Maria P. Gallego‐Hernanz, Eric Deconinck, Patrice Chevallier, Jürgen Finke, Jordi Esteve, Mohamad Mohty
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Total body irradiation plus fludarabine compared to busulfan plus fludarabine as "reduced-toxicity conditioning" for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT (2020)

Bone Marrow Transplantation
Sebastian Giebel, Myriam Labopin, Malgorzata Sobczyk-Kruszelnicka, Matthias Stelljes, Jenny L. Byrne, Nathalie Fegueux, Dietrich W. Beelen, Montserrat Rovira, Alexandros Spyridonidis, Didier Blaise, Martin Bornhäuser, Ihsan Karadogan, Bipin N. Savani, Arnon Nagler, Mohamad Mohty; Principal investigators of the contributing institutions
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease (2020)

Nature Communications
Daehong Kim, Giljun Park, Jani Huuhtanen, Sofie Lundgren, Rajiv K. Khajuria, Ana M. Hurtado, Cecilia Muñoz-Calleja, Laura Cardeñoso, Valle Gómez-García de Soria, Tzu Hua Chen-Liang, Samuli Eldfors, Pekka Ellonen, Sari Hannula, Matti Kankainen, Oscar Bruck, Anna Kreutzman, Urpu Salmenniemi, Tapio Lönnberg, Andrés Jerez, Maija Itälä-Remes, Mikko Myllymäki, Mikko A. I. Keränen, Satu Mustjoki
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2020)

Bone Marrow Transplantation
González-Barca E., Boumendil A., Blaise D., Trněný M., Masszi T., Finel H., Michieli M., Bittenbring J., Gritti G., Snowden J., Bishton M., Bruno B., de Villambrosia S., Janikova A., Leleu X., Anagnostopoulos A., Poiré X., Crysandt M., Özkurt Z., Vandenberghe E., Itälä-Remes M., Cahn J., Jantunen E., Schroyens W., Maertens J., Esquirol A., Dreger P., Montoto S., Sureda A., González-Barca E., Sureda A.
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
People search